A study to evaluate safety and feasibility of administrating Zoledronic acid to children and adolescents with acute lymphoblastic leukemia and lymphoma to prevent joint complication.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1075242

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Osteonecrosis (bone death) is a debilitating complication seen following chemotherapy for acute lymphoblastic leukemia in older children. It potentially could lead to destruction of joint, severely limiting quality of life and ultimately requiring joint replacement surgery. Currently there is no effective medical treatment to manage this. Based on our animal experiments we want to study if Zoledronic acid could prevent severe joint destruction in these children and improve their quality of life.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2014

Funding Scheme: NHMRC Postgraduate Scholarships

Funding Amount: $16,231.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Chemotherapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

acute lymphoblastic leukaemia (ALL) | bisphosphonates | cancer sequelae | clinical research | joint damage | paediatric | survivorship

Related Links